Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy

References

• OtakeKImuraTSakaiHAbeMDevelopment of a new preparation method of liposomes using supercritical carbon dioxideLangmuir2001171338983901
   Web of Science ®Google Scholar
• UhumwanghoMUOkorRSCurrent trends in the production and biomedical applications of liposomes: a reviewPak J Pharm Sci200541921
   Google Scholar
• JiskootWTeerlinkTBeuveryECCrommelinDJPreparation of liposomes via detergent removal from mixed micelles by dilution. The effect of bilayer composition and process parameters on liposome characteristicsPharm Weekbl Sci1986852592653786108
   PubMedGoogle Scholar
• DeamerQWPreparation and properties of ether-injection liposomesAnn N Y Acad Sci1978308250258279292
   PubMedGoogle Scholar
• SzokaFJrPapahadjopoulosDProcedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporationProc Natl Acad Sci U S A197875941944198279908
   PubMed Web of Science ®Google Scholar
• KimSMartinGMPreparation of cell-size unilamellar liposomes with high captured volume and defined size distributionBiochim Biophys Acta19816461197272296
   PubMed Web of Science ®Google Scholar
• MeureLAFosterNRDehghaniFConventional and dense gas techniques for the production of liposomes: a reviewAAPS Pharm Sci Tech200893798809
   PubMed Web of Science ®Google Scholar
• LesoinLBoutinOCramponCBadensECO2/water/surfactant ternary systems and liposome formation using supercritical CO2: a reviewColloid Surface Physicochem Eng Aspect20113771–3114
   Web of Science ®Google Scholar
• CastorTPPhospholipid nanosomesCurr Drug Deliv20052432934016305436
   PubMedGoogle Scholar
• JesorkaAOrwarOLiposomes: technologies and analytical applicationsAnnu Rev Anal Chem (Palo Alto Calif)2008180183220636098
   PubMed Web of Science ®Google Scholar
• MakinoKShibataAChapter 2: Surface properties of liposomes depending on their compositionLeitmannova LiuAAdvances in Planar Lipid Bilayers and LiposomesNetherlandsElsvier Science200644977
   Google Scholar
• IracheJMEsparzaIGamazoCAgüerosMEspuelasSNanomedicine: novel approaches in human and veterinary therapeuticsVet Parasitol20011801–2477121680101
   PubMed Web of Science ®Google Scholar
• ImmordinoMLDosioFCattelLStealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialInt J Nanomedicine20061329731517717971
   PubMed Web of Science ®Google Scholar
• ParkJWLiposome-based drug delivery in breast cancer treatmentBreast Cancer Res200243959912052251
   PubMed Web of Science ®Google Scholar
• BanghamADDiffusion of univalent ions across unilamellar of swollen phospholipidsJ Mol Biol1965132382525859039
   PubMed Web of Science ®Google Scholar
• AllenTMMoaseEHTherapeutic opportunities for targeted liposomal drug deliveryAdv Drug Deliv Rev1996212117133
   Web of Science ®Google Scholar
• Astellas Pharma US, Inc [homepage on the Internet]AmBisome® (Amphotericin B) liposome for injection Available from: http://www.ambisome.com/. Accessed November 11, 2011.
   Google Scholar
• MeunierFPrenticeHGRingdénOLiposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trialJ Antimicrob Chemother199128Suppl B83911778895
   PubMed Web of Science ®Google Scholar
• Enzon Pharmaceuticals, Inc [homepage on the Internet]ABELCET® (amphotericin B lipid complex) Injection Available from: http://enzon.com/. Accessed November 11, 2011.
   Google Scholar
• WasanKMLopez-BeresteinGCharacteristics of lipid-based formulations that influence their biological behavior in the plasma of patientsClin Infect Dis1996235112611388922813
   PubMed Web of Science ®Google Scholar
• DenningDWLeeJYHostetlerJSNIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosisAm J Med1994971351448059779
   PubMed Web of Science ®Google Scholar
• Three Rivers Pharmaceuticals, LLC. [homepage on the Internet]AMPHOTEC® Amphotericin B Cholesteryl Sulfate Complex for Injection Available from: http://www.3riverspharma.com/. Accessed November 11, 2011.
   Google Scholar
• Gilead Sciences, Inc [homepage on the Internet]DaunoXome® (daunorubicin citrate liposome injection) Available from: http://www.gilead.com/. Accessed November 11, 2011.
   Google Scholar
• RiveraELiposomal anthracyclines in metastatic breast cancer: clinical updateOncologist20038Suppl 23913679590
   PubMed Web of Science ®Google Scholar
• TomkinsonBBendeleRGilesFJOSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALLLeuk Res200327111039105012859997
   PubMed Web of Science ®Google Scholar
• HoarauDDelmasPDavidSRouxELerouxJCNovel long-circulating lipid nanocapsulesPharm Res200421101783178915553223
   PubMed Web of Science ®Google Scholar
• HongRLLiposomal anti-cancer drug researches the myth of long circulationJ Chinese Oncol Soc20042021021
   Google Scholar
• GardikisKTsimplouliCDimasKMicha-ScrettasMDemetzosCNew chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriersInt J Pharm20104021–223123720934501
   PubMed Web of Science ®Google Scholar
• ChowdharyRKShariffIDolphinDDrug release characteristics of lipid based benzoporphyrin derivativeJ Pharm Pharmaceut Sci2003611319
   PubMed Web of Science ®Google Scholar
• FahrAvan HoogevestPMaySBergstrandNS LeighMLTransfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug deliveryEur J Pharm Sci2005263–425126516112849
   PubMed Web of Science ®Google Scholar
• Novartis Ophthalmics, Inc [homepage on the Internet]Visudyne® (verteporfin for injection) Available from: http://www.visudyne.com/. Accessed November 11, 2011.
   Google Scholar
• Drugs.com [homepage on the Internet]DepoCyt® (cytarabine liposome injection) Prescribing Information Available from: http://www.drugs.com/pro/depocyt.html. Revised Sep 2011. Accessed November 11, 2011.
   Google Scholar
• Drugs.com [homepage on the Internet]DepoDur (morphine sulfate extended-release liposome injection) Prescribing Information Available from: http://www.drugs.com/pro/depodur.html. Revised Jan 2008. Accessed November 11, 2011.
   Google Scholar
• PatilSDBurgessDJLiposomes, design and manufacturingBurgessDJInjectable Dispersed Systems: Formulation, Processing and Performance (Drugs and The Pharmaceutical Sciences Series)New YorkMarcel Dekker2005249303
   Google Scholar
• UsonisVBakasénasVValentelisRKatilieneGVidzenieneDHerzogCAntibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal)Vaccine200321314588459214575771
   PubMed Web of Science ®Google Scholar
• D’AcremontVHerzogCGentonBImmunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderlyJ Travel Med2006132788316553593
   PubMed Web of Science ®Google Scholar
• The electronic Medicines Compendium (eMC) [homepage on the Internet]Epaxal Prescribing Information Available from: http://www.medicines.org.uk/EMC/medicine/12742/SPC/Epaxal/. Revised January 4, 2011. Accessed November 11, 2011.
   Google Scholar
• The electronic Medicines Compendium (eMC) [homepage on the Internet]INFLEXAL V Prescribing Information Available from: http://www.medicines.org.uk/emc/medicine/24941/SPC/inflexalv/. Revised Oct 2010. Accessed November 11, 2011.
   Google Scholar
• HerzogCHartmannKKünziVEleven years of Inflexal V-a virosomal adjuvanted influenza vaccineVaccine200927334381438719450630
   PubMed Web of Science ®Google Scholar
• ZhangJAAnyarambhatlaGMaLDevelopment and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulationEur J Pharm Biopharm200559117718715567316
   PubMed Web of Science ®Google Scholar
• CattaneoAGGornatiRSabbioniENanotechnology and human health: risks and benef itsJ Appl Toxicol201030873074421117037
   PubMed Web of Science ®Google Scholar
• MichaelisUHaasHTargeting of cationic liposomes to endothelial tissueGregoriadisGLiposome Technology, Volume III: Interactions of Liposomes with the Biological MilieuLondon, UKInforma Healthcare2007151170
   Google Scholar
• EichhornMEBeckerSStriethSPaclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imagingCancer Biol Ther200651899616357513
   PubMed Web of Science ®Google Scholar
• RobertBCampbellRBYingBKuestersGMHemphillRFighting cancer: from the bench to bedside using second generation cationic liposomal therapeuticsJ Pharm Sci200998241142918563780
   PubMed Web of Science ®Google Scholar
• LiZZhangYWurtzWCharacterization of nebulized liposomal amikacin (Arikace) as a function of droplet sizeJ Aerosol Med Pulm Drug Deliv200821324525418759656
   PubMed Web of Science ®Google Scholar
• MossalamMDixonASLimCSControlling subcellular delivery to optimize therapeutic effectTher Deliv20101116919321113240
   PubMedGoogle Scholar
• RodriguezMAPytlikRKozakTVincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 studyCancer2009115153475348219536896
   PubMed Web of Science ®Google Scholar
• KrishnaRWebbMSSt OngeGMayerLDLiposomal and non-liposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution propertiesJ Pharmacol Exp Ther200129831206121211504822
   PubMed Web of Science ®Google Scholar
• YarmolenkoPSZhaoYLandonCComparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumoursInt J Hyperthermia201026548549820597627
   PubMed Web of Science ®Google Scholar
• DromiSFrenkelVLukAPulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effectClin Cancer Res20071392722272717473205
   PubMed Web of Science ®Google Scholar
• ZahidSBrownellIRepairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapyJ Drugs Dermatol20087440540818459526
   PubMed Web of Science ®Google Scholar
• TariAMGutiérrez-PuenteYMonacoGLiposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenograftsInt J Oncol20073151243125017912453
   PubMed Web of Science ®Google Scholar
• PalAKhanSWangYFPreclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulationAnticancer Res2005251A33134115816556
   PubMed Web of Science ®Google Scholar
• DragovichTMendelsonDKurtinSRichardsonKVon HoffDHoosAA Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancerCancer Chemother Pharmacol200658675976416847673
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]Prostaglandin E1 (Liprostin) treatment with lower limb angioplasty for peripheral arterial occlusive disease Available from: http://clinicaltrials.gov/ct2/show/NCT00053716. Accessed November 11, 2011.
   Google Scholar
• PowellEChowLQBLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancerExpert Rev Respir Med200821374520477220
   PubMedGoogle Scholar
• OhyanagiFHoraiTSekineISafety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II studyJpn J Clin Oncol201141571872221393255
   PubMed Web of Science ®Google Scholar
• StathopoulosGPBoulikasTLipoplatin formulation review articleJ Drug Deliv2012201258136321904682
   PubMedGoogle Scholar
• YuNYConwayCPenaRLChenJYSTEALTH liposomal CKD-602, a topoisomerase I iInhibitor, improves the therapeutic index in human tumor xenograft modelsAnticancer Res2007274B2541254517695551
   PubMed Web of Science ®Google Scholar
• HwangJHLimMCSeoSSParkSYKangSPhase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervixJpn J Clin Oncol201141562462921355002
   PubMed Web of Science ®Google Scholar
• DuffaudFBornerMCholletPPhase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group studyEur J Cancer200440182748275215571957
   PubMed Web of Science ®Google Scholar
• SempleSCLeoneRWangJOptimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activityJ Pharm Sci20059451024103815793796
   PubMed Web of Science ®Google Scholar
• MrossKNiemannBMassingUPharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose studyCancer Chemother Pharmacol200454651452415322827
   PubMed Web of Science ®Google Scholar
• ShajiJPatoleVProtein and Peptide drug delivery: oral approachesIndian J Pharm Sci200870326927720046732
   PubMed Web of Science ®Google Scholar
• ChenCHanDCaiCTangXAn overview of liposome lyophilization and its future potentialJ Control Release2010142329931119874861
   PubMed Web of Science ®Google Scholar
• EL-NeserOHYahiyaSAEL-GazayerlyONEffect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomesSaudi Pharm J201018217224
   Google Scholar
• ClemonsKVStevensDAComparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosisAntimicrob Agents Chemother19984248999029559804
   PubMed Web of Science ®Google Scholar
• WuSYPutralLNLiangMDevelopment of a novel method for formulating stable siRNA-loaded lipid particles for in vivo usePharm Res200926351252219023647
   PubMed Web of Science ®Google Scholar
• RahmanAMYusufSWEwerMSAnthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulationInt J Nanomedicine20072456758318203425
   PubMed Web of Science ®Google Scholar
• LammersTHenninkWEStormGTumour-targeted nanomedicines: principles and practiceBr J Cancer200899339239718648371
   PubMed Web of Science ®Google Scholar
• HarrisLBatistGBeltRTLC D-99 Study GroupLiposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinomaCancer2002941253611815957
   PubMed Web of Science ®Google Scholar
• O’BrienMEWiglerNInbarMCAELYX Breast Cancer Study GroupReduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerAnn Oncol200415344044914998846
   PubMed Web of Science ®Google Scholar
• HongRLTsengYLPhase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumorCancer2001911826183311335910
   PubMed Web of Science ®Google Scholar
• TsengYLHongRLTaoMHChangFHSterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma modelInt J Cancer199980572373010048974
   PubMed Web of Science ®Google Scholar
• ChaoTCWangWSYenCCChiouTJLiuJHChenPMA dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancerCancer Invest200321683784714735687
   PubMed Web of Science ®Google Scholar
• HossannMWangTWiggenhornMSize of thermosensitive liposomes influences content releaseJ Control Release2010147343644320727921
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the Internet]Phase 3 study of ThermoDox with Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) Available from: http://clinicaltrials.gov/ct2/show/NCT00617981. Accessed November 11, 2011.
   Google Scholar
• MillsJKNeedhamDLysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transitionBiochim Biophys Acta200517162779616216216
   PubMed Web of Science ®Google Scholar
• NeedhamDAnyarambhatlaGKongGDewhirstMWA new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft modelCancer Res2000601197120110728674
   PubMed Web of Science ®Google Scholar
• BannoBIckensteinLMChiuGNThe functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivoJ Pharm Sci20109952295230819902527
   PubMed Web of Science ®Google Scholar
• O’ByrneKJThomasALSharmaRAA phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancerBr J Cancer2002871152012085249
   PubMed Web of Science ®Google Scholar
• ForssenEACoulterDMProffittRTSelective in vivo localisation of daunorubicin small unilamellar vesicles in solid tumorsCancer Res19925212325532611596882
   PubMed Web of Science ®Google Scholar
• ForssenEARossMEDaunoxome® treatment of solid tumors: preclinical and linical investigationsJ Liposome Res199441481512
   Google Scholar
• GillPSWernzJScaddenDTRandomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcomaJ Clin Oncol1996148235323648708728
   PubMed Web of Science ®Google Scholar
• SzebeniJComplement activation-related pseudoallergy: a new class of drug-induced acute immune toxicityToxicology200521610612116140450
   PubMed Web of Science ®Google Scholar
• MehtaRRBurkeTGMembrane biophysical parameters influencing anthracycline actionPriebeWAnthracycline AntibioticsNew YorkAmerican Chemical Society Publication2004222240
   Google Scholar
• FetterlyGJStraubingerRMPharmacokinetics of paclitaxel-containing liposomes in ratsAAPS Pharm Sci200354E32
   Google Scholar
• FetterlyGJGraselaTHShermanJWPharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxelClin Cancer Res200814185856586318794097
   PubMed Web of Science ®Google Scholar
• WinerEPBerryDAWoolfSFailure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B Trial 9342J Clin Oncol200422112061206815169793
   PubMed Web of Science ®Google Scholar
• BayraktarSBayraktarUDRocha-LimaCMRecent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancerWorld J Gastroenterol201016667368220135714
   PubMed Web of Science ®Google Scholar
• StegmannTMorseltHWBooyFPFunctional reconstitution of influenza virus envelopesEMBO J198769265126593678202
   PubMed Web of Science ®Google Scholar
• GlückRMischlerRBrantschenSJustMAlthausBCryzSJJrImmunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis AJ Clin Invest1992906249124951334977
   PubMed Web of Science ®Google Scholar
• NicholsonKGThompsonCIKlapJMSafety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulationsVaccine200928117117819799843
   PubMed Web of Science ®Google Scholar
• KanraGMarchisioPFeiterna-SperlingCComparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in childrenPediatr Infect Dis J200423430030615071282
   PubMed Web of Science ®Google Scholar
• BresslerNMBresslerSBPhotodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciencesInvest Ophthalmol Vis Sci200041362462810711673
   PubMed Web of Science ®Google Scholar
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study GroupArch Ophthalmol19991171329134510532441
   PubMed Web of Science ®Google Scholar
• Drugs.com [homepage on the Internet]MediGene reports additional phase II results of EndoTAG-1 for the treatment of triple receptor-negative breast cancer Prescribing Information Available from: http://www.drugs.com/clinical_trials/medigene-reports-additional-phase-ii-results-endotag-1-triple-receptor-negative-breast-cancer-9689.html. Posted Jun 2010. Accessed November 15, 2011.
   Google Scholar
• WhiteSCLoriganPMargisonGPPhase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancerBr J Cancer200695782282816969346
   PubMed Web of Science ®Google Scholar
• BooserDJEstevaFJRiveraEPhase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancerCancer Chemother Pharmacol20025016812111105
   PubMed Web of Science ®Google Scholar